在割抗性前列腺癌中,DHT合成中的功能增益突变
Kai-Hsiung Chang1, Rui Li2, Barbara Kuri3
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Division of Hematology/Oncology, Department of Internal Medicine and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
抗化前列腺癌 (CRPC) 可能会在3β-基类固醇脱酶1型 (3βHSD1) 中发生突变,导致二二 (DHT) 生产增加和瘤生长. 向3βHSD1可能为CRPC提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 生物化学 生物化学
背景情况:
- 前列腺癌细胞的生长依赖于雄激素受体 (AR) 刺激.
- 二激素 (DHT) 是主要的雌激素,由合成.
- 瘤往往复发作为割抵抗性前列腺癌 (CRPC) 后,素剥夺疗法.
研究的目的:
- 调查推动CRPC发展的机制.
- 确定CRPC治疗的新型治疗点.
主要方法:
- 对类固醇酶的特定突变进行CRPC分析.
- 评估发现突变对酶稳定性和功能的影响.
- 在突变酶的存在下量化DHT的产生.
主要成果:
- 在一些CRPC中发现了3β-hydroxysteroid脱酶1型 (3βHSD1) 的稳定性增益突变 (N367T).
- N367T突变赋予了对酶降解的抵抗力,导致积累.
- 突变的3βHSD1显著增强了脱氨转化为DHT,重新激活了AR信号.
结论:
- 由于稳定性突变的异常3βHSD1活性是CRPC进展的机制.
- 稳定的3βHSD1为CRPC中AR激活提供了DHT的来源.
- 3βHSD1代表了治疗CRPC的一个有前途的治疗点.
相关概念视频
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Dose-Response Relationship: Potency and Efficacy
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Transduction


